Balance Week 5

Heart Failure & Afib

B5LG1.1. Compare compensated and decompensated HFrEF in terms of cardiac function, blood pressure, and symptoms.

Answer: Compensated HFrEF has decreased LV contractility and EF, but increased SNS, RAAS, and ADH activity can preserve resting perfusion and arterial pressure. Decompensated HFrEF occurs when these mechanisms become inadequate or harmful, producing elevated filling pressures, pulmonary congestion, systemic edema, or reduced organ perfusion.

Extra Information:

• A patient may have EF 30% and normal resting blood pressure because increased SVR compensates for decreased CO.
• Compensation maintains circulation without correcting the original contractile defect.
• Chronic neurohormonal activation promotes ventricular remodeling and progressive dysfunction.

Source: [Lecture] Pearl HF Prework pp. 6–8 | Pearl HF LG pp. 3–4 | [First Aid] 2025 p. 316

B5LG1.1. Explain how decreased LV contractility changes end-systolic volume, stroke volume, ejection fraction, and cardiac output.

Answer: Decreased contractility → less blood ejected during systole → increased ESV → decreased SV → decreased EF and CO. SV = EDV − ESV, EF = SV/EDV, and CO = HR × SV.

Extra Information:

• EF measures the fraction of ventricular EDV ejected per beat, not the absolute volume ejected.
• Chronic fluid retention can increase EDV and partially restore SV despite a persistently low EF.
• An acute decrease in SV stimulates sympathetic compensation.

Source: [Lecture] Pearl HF Prework pp. 6, 30–31 | [First Aid] 2025 pp. 289–291

B5LG1.1. Why can chronic compensation eventually worsen heart failure?

Answer: Persistent SNS activation increases HR, contractility, and SVR, while RAAS and ADH promote sodium and water retention. These raise myocardial oxygen demand, afterload, preload, and ventricular wall stress, ultimately causing fibrosis, remodeling, congestion, and worsening systolic dysfunction.

Extra Information:

• Increased preload initially improves SV through Frank-Starling compensation.
• Excessive preload increases pulmonary venous pressure and edema.
• Chronic angiotensin II and aldosterone signaling promote myocardial remodeling.

Source: [Lecture] Pearl HF Prework pp. 7–10, 19–20 | [First Aid] 2025 p. 316

B5LG1.2. Explain the baroreceptor-mediated sympathetic response to decreased cardiac output in HFrEF.

Answer: Decreased CO → decreased effective arterial pressure → reduced carotid sinus and aortic arch baroreceptor firing → increased sympathetic activity. β1 stimulation increases HR and contractility, while α1 stimulation causes arteriolar and venous constriction.

Extra Information:

• Arteriolar constriction increases SVR and helps maintain MAP.
• Venoconstriction reduces venous capacitance and increases venous return.
• Chronic stimulation raises myocardial oxygen demand and promotes remodeling.

Source: [Lecture] Pearl HF Prework pp. 7–8 | Pearl HF LG p. 4 | [First Aid] 2025 p. 316

B5LG1.2. Explain the complete RAAS activation pathway in HFrEF and how it maintains blood pressure.

Answer: Decreased renal perfusion and increased β1 stimulation of juxtaglomerular cells → increased renin → angiotensinogen converted to angiotensin I → ACE produces angiotensin II → AT1 receptor activation increases vasoconstriction and aldosterone release → renal sodium and water retention increases circulating volume.

Extra Information:

• Angiotensin II increases afterload through vasoconstriction.
• Aldosterone promotes sodium reabsorption through mineralocorticoid receptor-mediated changes in ENaC and Na⁺/K⁺-ATPase activity.
• Prolonged activation promotes fibrosis and congestion.

Source: [Lecture] Pearl HF Prework pp. 7–8 | TWG HF pp. 12–15 | [First Aid] 2025 p. 316

B5LG1.2. Explain how ADH maintains blood pressure and contributes to dilutional hyponatremia in HFrEF.

Answer: Reduced effective arterial blood volume stimulates ADH release. ADH activates collecting-duct V2 receptors → Gs → cAMP → PKA → increased aquaporin-2 insertion → increased free-water reabsorption. Excess water retention can dilute plasma sodium while increasing total-body fluid volume.

Extra Information:

• V1 receptor stimulation also contributes to vasoconstriction.
• Total-body fluid overload can coexist with inadequate effective arterial perfusion.
• Hyponatremia may indicate substantial neurohormonal activation in advanced HF.

Source: [Lecture] Pearl HF Prework pp. 7–8, 43 | [First Aid] 2025 p. 316

B5LG1.3. State the Starling equation and explain how each variable influences transcapillary fluid exchange.

Answer: Jv = Kf[(Pc − Pi) − σ(πc − πi)]. Pc is capillary hydrostatic pressure, Pi is interstitial hydrostatic pressure, πc is capillary oncotic pressure, πi is interstitial oncotic pressure, Kf is the filtration coefficient, and σ is the protein reflection coefficient. Increased Pc favors filtration, while increased πc opposes filtration.

Extra Information:

• Increasing Kf increases filtration at a given pressure gradient.
• Decreased σ allows plasma proteins to cross the barrier more readily.
• Capillary permeability and pressure jointly determine edema formation.

Source: [Lecture] Pearl HF Prework p. 9 | Pearl HF LG pp. 6–7

B5LG1.3. Explain how increased pulmonary hydrostatic pressure causes cardiogenic pulmonary edema.

Answer: Decreased LV ejection → increased LVEDP → increased LA pressure → increased pulmonary venous pressure → increased pulmonary capillary hydrostatic pressure → increased filtration into lung interstitium. When fluid filtration exceeds lymphatic clearance, pulmonary interstitial and alveolar edema develop.

Extra Information:

• This mechanism is primarily hydrostatic rather than a primary permeability defect.
• Interstitial edema reduces lung compliance.
• Alveolar flooding produces impaired ventilation of perfused lung regions.

Source: [Lecture] Pearl HF Prework pp. 9, 11, 14 | [First Aid] 2025 p. 316

B5LG1.3. Apply the law of Laplace to explain why ventricular dilation increases myocardial wall stress.

Answer: Ventricular wall stress is approximately σ = Pr/(2h), where P is intraventricular pressure, r is chamber radius, and h is wall thickness. Increasing ventricular radius increases wall stress when pressure and wall thickness remain constant.

Extra Information:

• Increased wall stress raises myocardial oxygen demand.
• Chronic ventricular dilation may create a cycle of increased stress and further dysfunction.
• Wall thickening partially reduces wall stress but may contribute to abnormal remodeling.

Source: [Lecture] Pearl HF Prework p. 10 | [First Aid] 2025 p. 289

B5LG1.4. Explain step by step why HFrEF causes dyspnea on exertion despite acceptable resting blood pressure.

Answer: Exercise increases oxygen demand and venous return, but the failing LV has limited contractile reserve → inadequate increase in CO → increased LVEDP and LA pressure → increased pulmonary capillary hydrostatic pressure → interstitial edema and reduced lung compliance → increased work of breathing and dyspnea.

Extra Information:

• Decreased skeletal-muscle perfusion promotes earlier anaerobic metabolism and increased ventilatory drive.
• The patient may maintain normal resting blood pressure through increased SVR.
• Exertional symptoms often appear before overt resting pulmonary edema.

Source: [Lecture] Pearl HF Prework p. 11 | Pearl HF LG p. 5

B5LG1.4. Why does pulmonary interstitial edema increase the work of breathing?

Answer: Interstitial fluid accumulation reduces lung compliance, so a larger change in transpulmonary pressure is required to expand the lungs by the same volume. Pulmonary receptor stimulation and impaired mechanics increase respiratory effort and dyspnea.

Extra Information:

• Compliance = ΔV/ΔP.
• Decreased compliance means less volume expansion for the same pressure change.
• Fluid accumulation can stimulate rapid, shallow breathing.

Source: [Lecture] Pearl HF Prework p. 11 | Pearl HF LG pp. 5–7

B5LG1.4. Explain how pulmonary edema causes hypoxemia and inspiratory crackles.

Answer: Elevated pulmonary capillary pressure causes fluid accumulation in the interstitium and alveoli. Alveolar fluid decreases ventilation relative to perfusion, producing V/Q mismatch and potentially shunt physiology. Reopening of small fluid-affected airways and alveolar units during inspiration contributes to crackles.

Extra Information:

• Severe alveolar flooding reduces effective gas exchange.
• Pulmonary edema also reduces lung compliance.
• Crackles support pulmonary congestion but are not specific for heart failure.

Source: [Lecture] Pearl HF Prework p. 14 | B5 Heart Failure Pathology p. 14 | [First Aid] 2025 p. 316

B5LG1.5. Explain how acute myocardial infarction can rapidly produce systolic heart failure and pulmonary edema.

Answer: Coronary occlusion → myocardial ischemia and loss of contractility → increased ESV and decreased SV → decreased CO and increased LVEDP → increased LA and pulmonary venous pressure → increased pulmonary capillary filtration → pulmonary edema and dyspnea.

Extra Information:

• Acute dysfunction may occur before chronic volume compensation develops.
• Severe dysfunction can cause hypotension and cardiogenic shock.
• Infarct size and successful reperfusion influence recovery.

Source: [Lecture] Pearl HF Prework p. 14 | Structure ICG pp. 1–2 | [First Aid] 2025 pp. 308–310

B5LG1.5. Distinguish myocardial stunning from irreversible myocardial infarction.

Answer: Myocardial stunning is persistent but reversible contractile dysfunction after transient ischemia despite restoration of coronary flow. Myocardial infarction causes irreversible cardiomyocyte necrosis, followed by inflammatory removal and replacement with noncontractile scar tissue.

Extra Information:

• Stunning can produce regional hypokinesis even after successful revascularization.
• The Structure case describes EF improving from 35% to 55%.
• Recovery of viable myocardium differs from regeneration of infarcted myocardium.

Source: [Lecture] Structure ICG pp. 1–2 | B5 Heart Failure Pathology pp. 3–6

B5LG1.5. Why does acute LV dysfunction increase pulmonary venous pressure even when forward cardiac output decreases?

Answer: Decreased LV contractility leaves more blood in the ventricle after systole. Increased ESV and filling volume raise LVEDP, which is transmitted backward through the LA and pulmonary veins, increasing pulmonary capillary hydrostatic pressure.

Extra Information:

• Reduced CO reflects impaired forward flow.
• Elevated LVEDP reflects impaired emptying and increased filling pressure.
• Both processes occur simultaneously during acute decompensation.

Source: [Lecture] Pearl HF Prework pp. 14, 30–31 | Structure ICG p. 2

B5LG1.6. Explain where BNP is produced, what stimulates its release, and how proBNP is processed.

Answer: Ventricular cardiomyocytes synthesize proBNP in response to increased myocardial wall stretch. ProBNP is processed into active BNP and inactive NT-proBNP, both of which can be measured clinically.

Extra Information:

• Increased ventricular filling pressure and volume overload promote BNP production.
• BNP activates natriuretic peptide receptors.
• NT-proBNP serves as a biomarker but has no significant direct natriuretic activity.

Source: [Lecture] Pearl HF Prework p. 15 | Structure ICG pp. 2–3 | [First Aid] 2025 p. 299

B5LG1.6. Explain BNP receptor signaling and its effects on the kidneys and systemic vasculature.

Answer: BNP binds natriuretic peptide receptors associated with particulate guanylyl cyclase → increased intracellular cGMP → vascular smooth-muscle relaxation and increased renal sodium excretion. These actions decrease circulating volume and vascular resistance.

Extra Information:

• Natriuresis promotes water excretion.
• BNP physiologically opposes excessive RAAS-mediated sodium retention.
• Its effects may be insufficient to overcome advanced heart failure.

Source: [Lecture] Pearl HF Prework p. 15 | TWG HF pp. 14–15 | [First Aid] 2025 p. 299

B5LG1.6. Why is NT-proBNP generally preferred over BNP when assessing response to sacubitril/valsartan?

Answer: Sacubitril inhibits neprilysin, an enzyme involved in BNP breakdown. BNP levels may increase because degradation decreases. NT-proBNP is not degraded by neprilysin, so changes more reliably reflect alterations in myocardial wall stress during ARNI treatment.

Extra Information:

• BNP and NT-proBNP support diagnosis and risk assessment.
• Neither biomarker independently establishes the cause of HF.
• Interpret biomarker trends with symptoms, renal function, and imaging.

Source: [Lecture] TWG HF pp. 14–15 | Pearl HF Prework p. 15 | [First Aid] 2025 p. 299

B5LG1.7. Predict how the cardiac function curve changes immediately after acute loss of LV contractility.

Answer: Decreased contractility shifts the cardiac function curve downward. At a given filling pressure, the heart generates less cardiac output. The immediate equilibrium moves toward lower CO and higher right atrial or filling pressure.

Extra Information:

• This is a change in intrinsic pumping function, not simply movement along the same curve.
• Acute compensation is initially incomplete.
• Reduced CO stimulates SNS, RAAS, and ADH.

Source: [Lecture] Pearl HF Prework pp. 16–18 | [First Aid] 2025 pp. 290–291

B5LG1.7. Explain how chronic fluid retention and sympathetic venoconstriction shift the venous return curve.

Answer: RAAS-mediated sodium and water retention increases blood volume, while sympathetic venoconstriction decreases venous capacitance. Both increase mean systemic filling pressure (Pms), shifting the venous return curve rightward.

Extra Information:

• Venous return depends on the pressure difference between Pms and right atrial pressure.
• Increased Pms can partially restore cardiac output.
• The higher operating filling pressure increases congestion risk.

Source: [Lecture] Pearl HF Prework pp. 16–18

B5LG1.7. Compare acute and chronic HFrEF using the intersection of cardiac and venous return curves.

Answer: Acute HFrEF shifts the cardiac function curve downward, lowering CO. Chronic compensation increases blood volume and venous tone, shifting the venous return curve rightward. This moves the equilibrium toward improved CO but at an abnormally high filling pressure.

Extra Information:

• Increased SVR can also reduce the slope of the venous return curve by increasing resistance to venous return.
• Chronic compensation does not restore normal intrinsic contractility.
• Excessive filling pressure promotes pulmonary edema.

Source: [Lecture] Pearl HF Prework pp. 16–18, 24

B5LG1.8. Identify major triggers of decompensation in chronic HFrEF and explain their shared hemodynamic consequences.

Answer: Triggers include ischemia or MI, arrhythmias, uncontrolled hypertension, excess sodium intake, medication withdrawal, infection, anemia, pulmonary embolism, and renal dysfunction. They decrease effective forward flow, increase preload or afterload, or increase circulatory demand beyond available cardiac reserve.

Extra Information:

• Hypertension increases resistance to ventricular ejection.
• Renal dysfunction promotes fluid accumulation.
• Infection and anemia can increase cardiac workload.

Source: [Lecture] Pearl HF Prework p. 19

B5LG1.8. Explain why rapid atrial fibrillation can precipitate acute decompensation in HFrEF.

Answer: Atrial fibrillation eliminates coordinated atrial contraction, decreasing ventricular filling contribution. Rapid ventricular rates shorten diastolic filling time, increase myocardial oxygen demand, and may reduce stroke volume, especially when ventricular reserve is already limited.

Extra Information:

• Atrial arrhythmias can raise filling pressures and worsen dyspnea.
• The impact depends on ventricular function and rate.
• Improving ventricular rate or restoring appropriate rhythm can improve hemodynamics.

Source: [Lecture] Pearl HF Prework p. 19 | [First Aid] 2025 pp. 311, 316

B5LG1.8. Why can excess sodium intake or discontinuation of loop diuretics cause pulmonary edema?

Answer: Sodium retention expands extracellular and intravascular fluid volume → increased venous return and EDV → increased LVEDP in the failing ventricle → increased pulmonary venous and capillary hydrostatic pressure → pulmonary edema.

Extra Information:

• Increasing preload may initially increase SV.
• Beyond the useful Frank-Starling range, additional filling mainly increases congestion.
• Loop diuretics reverse this process by promoting renal sodium and water excretion.

Source: [Lecture] Pearl HF Prework pp. 19, 42–46 | TWG HF p. 20

B5LG2.1. Classify acute heart failure medications by their primary hemodynamic effects.

Answer:

• Dobutamine increases contractility.

• Milrinone increases contractility and decreases SVR.

• Nitroprusside decreases preload and afterload.

• Nitroglycerin primarily decreases preload at lower doses.

• Furosemide decreases circulating volume and preload.

Extra Information:

• Increasing contractility may increase SV in low-output states.

• Decreasing afterload reduces resistance to LV ejection.

• Decreasing preload relieves pulmonary venous congestion.

Source: [Lecture] TWG HF pp. 42–45

B5LG2.1. Explain why positive inotropes can increase stroke volume without increasing preload.

Answer: Positive inotropes increase myocardial contractile force at a given filling volume. Greater systolic ejection decreases ESV, thereby increasing SV = EDV − ESV.

Extra Information:

• Dobutamine acts mainly through β1-mediated cAMP signaling.
• Milrinone inhibits PDE3, preventing cAMP breakdown.
• Increased intracellular calcium supports stronger contraction.

Source: [Lecture] TWG HF p. 44 | [First Aid] 2025 pp. 289–291

B5LG2.1. Why can an arterial vasodilator increase stroke volume in systolic heart failure without directly increasing contractility?

Answer: Arterial vasodilation decreases SVR and LV afterload, reducing the pressure against which the failing ventricle must eject blood. More blood can be expelled at the same intrinsic contractility, decreasing ESV and increasing SV.

Extra Information:

• Nitroprusside produces both arterial and venous dilation.
• Excessive vasodilation can cause hypotension.
• The benefit depends on maintaining adequate systemic perfusion.

Source: [Lecture] TWG HF pp. 42, 45

B5LG2.2. Explain dobutamine's mechanism and intracellular signaling pathway.

Answer: Dobutamine predominantly stimulates myocardial β1 receptors → Gs activation → increased adenylyl cyclase activity → increased cAMP → increased PKA signaling → increased calcium availability → increased myocardial contractility and SV.

Extra Information:

• It is a positive inotrope used for selected acute low-output states.
• β2 activity can contribute to vascular relaxation.
• Excessive cardiac stimulation can worsen ischemia.

Source: [Lecture] TWG HF pp. 44, 46 | [First Aid] 2025 pp. 241, 289

B5LG2.2. Describe the ADME of dobutamine and explain why it must be administered by continuous IV infusion.

Answer: Dobutamine is administered IV because oral administration is unsuitable for its rapid parenteral use. It has rapid onset, a plasma half-life of approximately 2 minutes, and is metabolized mainly by catechol methylation and conjugation, with metabolites eliminated in urine.

Extra Information:

• The short half-life permits rapid dose titration.
• Effects begin within approximately 1–2 minutes.
• The inactive 3-O-methyl metabolite is among the urinary products.

Source: [Lecture] TWG HF p. 44 | [Drug Label] DailyMed Dobutamine Injection, Clinical Pharmacology

B5LG2.2. Explain nitroglycerin's mechanism, ADME, and major adverse effects.

Answer: Nitroglycerin produces nitric oxide-mediated activation of soluble guanylyl cyclase → increased cGMP → vascular smooth-muscle relaxation. It is used sublingually, topically, or IV depending on indication. It has rapid metabolism and a short plasma half-life of approximately 3 minutes.

Extra Information:

• Venodilation decreases preload and pulmonary congestion.
• Adverse effects include headache, hypotension, and tolerance.
• PDE5 inhibitors can produce dangerous additive hypotension.

Source: [Lecture] TWG HF p. 45 | [Drug Label] DailyMed Nitroglycerin Injection, Pharmacokinetics

B5LG2.2. Explain furosemide's mechanism, ADME, and electrolyte adverse effects.

Answer: Furosemide inhibits NKCC2 in the thick ascending limb, causing increased NaCl and water excretion. It can be given orally or IV, has variable oral bioavailability, is highly protein-bound, reaches the tubular lumen through proximal secretion, and is eliminated substantially through the kidneys.

Extra Information:

• Adverse effects include hypokalemia, hypomagnesemia, metabolic alkalosis, hyperuricemia, and ototoxicity.
• Intestinal edema may delay or impair effective oral drug delivery during decompensation.
• IV treatment is useful when rapid and reliable diuresis is required.

Source: [Lecture] TWG HF p. 20 | [First Aid] 2025 p. 614 | [Research] NCBI Bookshelf, Furosemide Pharmacokinetics

B5LG2.2. Explain why chronic β-blockers and spironolactone improve HFrEF despite different acute physiological effects.

Answer: β-blockers reduce chronic catecholamine stimulation, myocardial oxygen demand, renin release, and adverse remodeling. Spironolactone blocks mineralocorticoid receptors, reducing aldosterone-mediated sodium retention, potassium excretion, fibrosis, and remodeling.

Extra Information:

• β-blockers initially reduce contractility but improve long-term outcomes.
• Spironolactone can cause hyperkalemia and gynecomastia.
• Both are disease-modifying therapies rather than simply symptomatic treatments.

Source: [Lecture] TWG HF pp. 21, 23 | [First Aid] 2025 p. 316

B5LG2.3. Explain the mechanisms by which ACE inhibitors, ARBs, and ARNIs reduce chronic HFrEF progression.

Answer: ACE inhibitors decrease angiotensin II synthesis and bradykinin degradation. ARBs block AT1 receptors. ARNIs combine AT1 blockade with neprilysin inhibition, increasing beneficial natriuretic peptide activity. These mechanisms reduce vasoconstriction, sodium retention, and maladaptive remodeling.

Extra Information:

• ACE inhibitors can cause cough and angioedema through increased bradykinin.
• ARBs generally cause less cough.
• ARNIs require a 36-hour ACE inhibitor washout.

Source: [Lecture] TWG HF pp. 12–18 | [First Aid] 2025 p. 316

B5LG2.3. Describe sacubitril/valsartan ADME, including formation and elimination of the active neprilysin inhibitor.

Answer: Oral sacubitril is converted by esterases to active LBQ657, while valsartan blocks AT1 receptors. Sacubitril, LBQ657, and valsartan are highly plasma protein-bound. LBQ657 is eliminated through urine and feces, whereas valsartan is eliminated predominantly in feces.

Extra Information:

• Approximate half-lives are sacubitril 1.4 hours, LBQ657 11.5 hours, and valsartan 9.9 hours.
• LBQ657 provides neprilysin inhibition.
• Renal impairment can increase LBQ657 exposure.

Source: [Lecture] TWG HF pp. 14–18 | [Drug Label] DailyMed Entresto, Pharmacokinetics

B5LG2.3. Explain the renal mechanism of SGLT2 inhibitors and why they improve HFrEF outcomes without requiring diabetes.

Answer: SGLT2 inhibitors block proximal-tubule sodium-glucose reabsorption → increased urinary glucose and sodium excretion → osmotic diuresis and natriuresis. Increased distal NaCl delivery also restores tubuloglomerular feedback, helping reduce intraglomerular pressure.

Extra Information:

• Dapagliflozin and empagliflozin have demonstrated HF benefits in patients without diabetes.
• Benefits include reduced HF hospitalization.
• Their effects extend beyond blood glucose reduction.

Source: [Lecture] TWG HF pp. 25–27 | [First Aid] 2025 pp. 316, 358

B5LG2.3. Describe dapagliflozin ADME and identify the major drug-handling pathway.

Answer: Dapagliflozin is orally administered, approximately 78% bioavailable, and approximately 91% protein-bound. It is metabolized primarily by UGT1A9 to an inactive glucuronide, with drug-related products eliminated predominantly in urine. Its terminal half-life is approximately 12.9 hours.

Extra Information:

• CYP metabolism is a minor clearance pathway.
• Less than 2% of the dose is recovered unchanged in urine.
• It can be taken with or without food.

Source: [Lecture] TWG HF p. 25 | [Drug Label] DailyMed Dapagliflozin, Section 12.3

B5LG2.3. Explain why the four foundational HFrEF drug classes are used together rather than selecting only one mechanism.

Answer: ARNI/ACEI/ARB reduces harmful RAAS signaling, β-blockers suppress chronic sympathetic toxicity, MRAs reduce aldosterone-mediated remodeling, and SGLT2 inhibitors provide additional renal and cardiovascular protection. Their complementary actions improve outcomes more than relying on a single pathway.

Extra Information:

• Loop diuretics are added for congestion.
• Start and titrate therapies according to blood pressure, potassium, renal function, and stability.
• Multiple neurohormonal systems contribute simultaneously to HF progression.

Source: [Lecture] TWG HF pp. 34–40 | [First Aid] 2025 p. 316

B5LG2.4. Explain carvedilol receptor pharmacology and its effects on chronic HFrEF.

Answer: Carvedilol blocks β1, β2, and α1 receptors. β1 blockade decreases HR, renin release, and chronic catecholamine toxicity, while α1 blockade produces vasodilation and reduced peripheral resistance. Long-term treatment limits remodeling and improves survival.

Extra Information:

• Start at low doses after clinical stabilization.
• Monitor HR, BP, dizziness, fatigue, and congestion.
• Unlike selective β1 blockers, carvedilol has additional α1-blocking activity.

Source: [Lecture] TWG HF p. 23 | [First Aid] 2025 pp. 244, 316

B5LG2.4. Describe carvedilol's important pharmacokinetic properties and why liver disease matters.

Answer: Carvedilol is orally absorbed but undergoes substantial hepatic first-pass metabolism. It is highly protein-bound and undergoes hepatic metabolism, including CYP2D6 and CYP2C9 pathways, with elimination predominantly through bile and feces.

Extra Information:

• Food can slow absorption and reduce orthostatic effects.
• Severe hepatic impairment can significantly alter drug exposure.
• Its pharmacodynamic effects require monitoring beyond plasma concentration.

Source: [Lecture] TWG HF p. 23 | [Drug Label] DailyMed Carvedilol, Clinical Pharmacology

B5LG2.4. Compare carvedilol, metoprolol succinate, and bisoprolol by receptor selectivity and HFrEF benefit.

Answer: Carvedilol blocks β1, β2, and α1 receptors. Metoprolol succinate and bisoprolol are predominantly β1-selective. These three evidence-based agents reduce mortality and hospitalization when appropriately used in chronic HFrEF.

Extra Information:

• Metoprolol succinate is extended-release.
• β1 blockade lowers myocardial sympathetic stimulation and renin release.
• β-blockers should be titrated after stabilization, rather than initiated during active shock.

Source: [Lecture] TWG HF p. 23 | [First Aid] 2025 p. 316

B5LG2.4. Explain the adverse effects and precautions associated with chronic SGLT2 inhibitors.

Answer: SGLT2 inhibitors can cause genital fungal infections, volume depletion, hypotension, and euglycemic ketoacidosis. Renal function and volume status should be assessed, particularly when treatment is combined with diuretics.

Extra Information:

• Glucosuria increases genital fungal infection risk.
• The lecture recommends withholding these agents before surgery because fasting and stress increase ketoacidosis risk.
• An initial modest eGFR decrease can occur through altered renal hemodynamics.

Source: [Lecture] TWG HF p. 25 | [Drug Label] DailyMed Dapagliflozin, Warnings and Precautions

B5LG2.4. Why is β-blocker initiation delayed during active severe HFrEF decompensation?

Answer: β-blockers acutely decrease heart rate and myocardial contractility, which can further reduce cardiac output during shock or severe hypoperfusion. The long-term benefit develops through neurohormonal suppression and remodeling prevention after hemodynamic stabilization.

Extra Information:

• Chronic therapy may be continued during uncomplicated congestion if tolerated.
• Severe hypotension or shock may require temporary dose reduction or withholding.
• Starting low and titrating gradually reduces clinical deterioration risk.

Source: [Lecture] TWG HF pp. 23, 51 | [First Aid] 2025 p. 316

B5LG2.5. Distinguish acute and chronic indications for loop diuretics in HFrEF.

Answer: Acute decompensated HF with pulmonary or systemic congestion often requires IV loop diuretics for rapid fluid removal. Chronic HF may require oral loop diuretics to maintain euvolemia and prevent recurrent congestion.

Extra Information:

• Indications include orthopnea, crackles, elevated JVP, peripheral edema, and increasing weight.
• Diuretics improve congestion but do not replace foundational mortality-reducing therapy.
• Dose requirements change with renal function and dietary sodium intake.

Source: [Lecture] TWG HF pp. 20, 36, 42

B5LG2.5. Explain why loop diuretics improve pulmonary edema through changes in preload and Starling forces.

Answer: Loop diuretics increase renal sodium and water excretion → decreased circulating volume → decreased venous return and ventricular filling pressure → decreased pulmonary capillary hydrostatic pressure → reduced fluid filtration and improved pulmonary congestion.

Extra Information:

• Reduced capillary filtration permits lymphatic clearance of accumulated interstitial fluid.
• Excessive diuresis can cause low preload and hypoperfusion.
• Improvement is assessed through symptoms, examination, weight, and urine output.

Source: [Lecture] TWG HF p. 20 | Pearl HF Prework pp. 9, 14

B5LG2.5. Which clinical measurements should be monitored during aggressive loop diuresis, and why?

Answer: Monitor urine output, weight, blood pressure, signs of congestion, creatinine, sodium, potassium, and magnesium. Excessive sodium and water loss can produce hypovolemia and kidney dysfunction, while potassium and magnesium depletion increase arrhythmia risk.

Extra Information:

• Hypokalemia and hypomagnesemia can contribute to ventricular arrhythmias.

• Metabolic alkalosis can result from increased distal sodium delivery and enhanced H⁺ secretion.

• Clinical decongestion should occur without unacceptable loss of perfusion.

• Loop diuretics (furosemide) block NKCC2 → less K⁺ recycling → reduced lumen-positive voltage → decreased Ca²⁺ and Mg²⁺ reabsorption → increased urinary Ca²⁺ and Mg²⁺.

Source: [Lecture] TWG HF pp. 20, 36

B5LG3.1. Compare primary and secondary hemostasis by cellular components, molecular mechanisms, and bleeding patterns.

Answer: Primary hemostasis uses platelets and VWF to form an initial platelet plug and commonly causes mucocutaneous bleeding when defective. Secondary hemostasis uses thrombin generation and cross-linked fibrin to stabilize the plug and commonly causes deep hematomas, hemarthroses, and delayed bleeding when defective.

Extra Information:

• Platelet defects may cause petechiae, epistaxis, and menorrhagia.
• Coagulation factor deficiencies often cause deep tissue bleeding.
• Some disorders, especially VWD, affect both processes.

Source: [Lecture] Applied Coagulation PFN p. 25 | B5LG3B Applied Coagulation pp. 2–4 | [First Aid] 2025 pp. 418–419

B5LG3.1. Explain platelet adhesion, activation, and aggregation in primary hemostasis.

Answer: Endothelial injury exposes subendothelial collagen and VWF. Platelet GPIb binds VWF, supporting adhesion. Activated platelets release ADP and produce thromboxane A2, recruiting additional platelets. Activated GPIIb/IIIa binds fibrinogen, linking platelets together.

Extra Information:

• VWF is essential for platelet adhesion under high-shear conditions.
• ADP activates platelet P2Y12 receptors.
• Fibrin later stabilizes the primary platelet plug.

Source: [Lecture] Applied Coagulation PFN pp. 6–10 | [First Aid] 2025 pp. 418–419

B5LG3.1. Describe intrinsic, extrinsic, and common coagulation pathways and identify the laboratory tests used for each.

Answer: Intrinsic pathway: XII → XI → IX with VIII as cofactor → X. Extrinsic pathway: tissue factor and VIIa → X. Common pathway: Xa with Va converts II to IIa, which converts fibrinogen I to fibrin, subsequently cross-linked by XIIIa. aPTT measures intrinsic and common pathways, while PT measures extrinsic and common pathways.

Extra Information:

• PT is sensitive to factor VII activity.
• aPTT detects abnormalities in factors VIII, IX, XI, and XII.
• Factor XIII deficiency can cause bleeding with normal PT and aPTT.

Source: [Lecture] Applied Coagulation PFN pp. 11–17 | [First Aid] 2025 pp. 418–419

B5LG3.1. Explain why the traditional intrinsic/extrinsic cascade does not fully represent coagulation in vivo.

Answer: The laboratory model separates artificial contact activation and tissue factor activation to interpret aPTT and PT. In vivo, exposed tissue factor activates FVII, initiating activation of IX and X, while thrombin amplifies coagulation through factors V, VIII, and XI.

Extra Information:

• Factor XII is important in contact-based laboratory testing.
• Factor XII is not required for normal physiological hemostasis.
• Tissue factor exposure provides the major initiating signal during vascular injury.

Source: [Lecture] Applied Coagulation PFN pp. 5–8 | [First Aid] 2025 p. 418

B5LG3.1. Interpret isolated prolonged PT, isolated prolonged aPTT, and prolongation of both tests.

Answer: Isolated prolonged PT suggests factor VII or extrinsic-pathway dysfunction. Isolated prolonged aPTT suggests intrinsic-pathway factor deficiency or inhibitor. Prolongation of both tests suggests multiple factor abnormalities or common-pathway dysfunction involving factors X, V, II, or fibrinogen.

Extra Information:

• Early vitamin K deficiency often prolongs PT first.
• Hemophilia A and B usually prolong aPTT.
• DIC and advanced liver disease can prolong both PT and aPTT.

Source: [Lecture] Applied Coagulation PFN pp. 12–21, 30 | [First Aid] 2025 p. 418

B5LG3.2. Explain how liver dysfunction impairs synthesis of procoagulant and anticoagulant proteins.

Answer: Hepatocytes produce most coagulation factors and important anticoagulant proteins, including proteins C and S and antithrombin. Severe liver dysfunction decreases synthesis of multiple components, disturbing both clot formation and physiological anticoagulation.

Extra Information:

• Factor VIII and VWF may remain normal or increase because of important extrahepatic production.
• Thrombocytopenia can result from splenic sequestration and reduced thrombopoietin.
• Increased INR does not necessarily imply protection from thrombosis.

Source: [Lecture] Applied Coagulation PFN pp. 28, 30 | [First Aid] 2025 pp. 418–419

B5LG3.2. Explain how factor V helps distinguish liver failure from isolated vitamin K deficiency.

Answer: Factor V is synthesized by the liver but does not require vitamin K-dependent γ-carboxylation. Severe liver synthetic dysfunction can decrease factor V activity, whereas isolated vitamin K deficiency primarily decreases factors II, VII, IX, and X and usually preserves factor V.

Extra Information:

• Protein C and S are also vitamin K-dependent.
• Factor VII decreases rapidly because of its short half-life.
• Severe hepatic disease may produce complex abnormalities beyond a single factor deficiency.

Source: [Lecture] Applied Coagulation PFN pp. 26–30 | [First Aid] 2025 p. 419

B5LG3.2. Explain the pathophysiology and expected coagulation findings of DIC.

Answer: Systemic coagulation activation generates widespread thrombin and microvascular fibrin deposition. Continued clot formation consumes platelets and coagulation factors while fibrinolysis generates fibrin degradation products. Typical findings include low platelets, low fibrinogen, increased D-dimer, and prolonged PT and aPTT.

Extra Information:

• DIC may cause both microvascular thrombosis and severe bleeding.
• Common triggers include sepsis, malignancy, trauma, and obstetric complications.
• Elevated D-dimer reflects degradation of cross-linked fibrin.

Source: [Lecture] Applied Coagulation PFN p. 29 | B5LG3B Applied Coagulation pp. 14–18

B5LG3.2. Why can thrombosis occur in severe liver disease despite prolonged PT/INR?

Answer: Liver failure decreases both procoagulant factors and natural anticoagulants, including protein C, protein S, and antithrombin. PT/INR reflects selected procoagulant pathways but does not measure the entire rebalanced hemostatic system.

Extra Information:

• Patients with cirrhosis can experience venous thrombosis.
• Platelet number, VWF activity, and fibrinolysis also affect hemostasis.
• INR is useful for warfarin monitoring but does not fully quantify bleeding risk in liver disease.

Source: [Lecture] Applied Coagulation PFN pp. 28–30

B5LG3.2. Use laboratory findings to distinguish hemophilia A, vitamin K deficiency, advanced liver disease, and DIC.

Answer: Hemophilia A usually causes isolated prolonged aPTT and low factor VIII. Vitamin K deficiency commonly increases PT first with preserved factor V. Liver disease may prolong both tests with reduced factor V. DIC commonly produces prolonged PT/aPTT, low platelets, low fibrinogen, and elevated D-dimer.

Extra Information:

• VWD can variably prolong aPTT because VWF stabilizes factor VIII.
• A mixing study distinguishes deficiencies from inhibitors.
• The clinical bleeding or thrombosis phenotype remains essential.

Source: [Lecture] Applied Coagulation PFN p. 30 | B5LG3B Applied Coagulation pp. 5–18 | [First Aid] 2025 pp. 418–419

B5LG3.3. Compare arterial and venous thrombi by hemodynamic conditions and composition.

Answer: Arterial thrombi often form under high shear after plaque rupture or endothelial injury and are relatively platelet-rich. Venous thrombi commonly develop under low-flow conditions with stasis or hypercoagulability and are relatively fibrin- and red-cell-rich.

Extra Information:

• Both thrombus types contain platelets and fibrin.
• Arterial thrombosis may cause MI or ischemic stroke.
• Venous thrombosis can cause DVT and pulmonary embolism.

Source: [Lecture] Applied Coagulation PFN p. 31

B5LG3.3. Explain the clinical differences between acute arterial occlusion and venous thrombosis.

Answer: Arterial occlusion reduces downstream blood delivery, producing ischemia, severe pain, pallor, pulselessness, paresthesias, paralysis, and temperature changes. Venous thrombosis impairs blood drainage, causing swelling, warmth, tenderness, and venous congestion.

Extra Information:

• Arterial occlusion can threaten tissue viability rapidly.
• DVT may produce unilateral leg swelling.
• Venous thrombi can embolize to pulmonary arteries.

Source: [Lecture] Applied Coagulation PFN p. 31 | [First Aid] 2025 pp. 321, 691

B5LG3.3. Explain Virchow's triad and provide a mechanism for each component.

Answer: Virchow's triad includes endothelial injury, abnormal blood flow or stasis, and hypercoagulability. Endothelial injury exposes procoagulant surfaces, stasis reduces clearance of activated clotting factors, and hypercoagulability increases thrombin generation or decreases natural anticoagulant activity.

Extra Information:

• Immobilization promotes stasis.
• Factor V Leiden promotes resistance to activated protein C.
• Malignancy can create a systemic prothrombotic state.

Source: [Lecture] Applied Coagulation PFN pp. 31–32 | [First Aid] 2025 pp. 419, 691

B5LG3.3. Why are antiplatelet therapies emphasized in many arterial thrombotic conditions while anticoagulants are central to venous thrombosis treatment?

Answer: Platelet adhesion and aggregation are major drivers of thrombus formation under high arterial shear. Venous thrombosis relies heavily on activation of the coagulation cascade and fibrin accumulation, making factor Xa or thrombin inhibition effective at preventing propagation.

Extra Information:

• Aspirin decreases thromboxane A2 production.
• P2Y12 inhibitors reduce ADP-dependent platelet activation.
• Anticoagulants prevent clot extension rather than directly dissolving established fibrin.

Source: [Lecture] Applied Coagulation PFN pp. 31, 33–34 | [First Aid] 2025 pp. 441–442

B5LG3.3. Explain why pulmonary embolism can produce acute obstructive shock.

Answer: Large pulmonary arterial obstruction abruptly increases pulmonary vascular resistance and RV afterload. RV dilation and reduced forward pulmonary flow impair LV filling, decreasing systemic cardiac output and potentially causing profound hypotension and shock.

Extra Information:

• Acute PE can cause dyspnea, tachycardia, pleuritic pain, and hypoxemia.
• Ventilated but unperfused alveoli increase physiological dead space.
• Massive PE is a potential indication for reperfusion therapy.

Source: [First Aid] 2025 p. 691 | [Lecture] B5LG4 Pharmacology pp. 8–9, 21

B5LG4.1. Explain the molecular mechanism by which unfractionated heparin inhibits coagulation.

Answer: UFH binds antithrombin through a pentasaccharide sequence, accelerating antithrombin inhibition of thrombin IIa and factor Xa. Long chains are necessary to bridge antithrombin and thrombin, whereas anti-Xa activity requires the antithrombin-binding sequence.

Extra Information:

• UFH has approximately equal anti-Xa and anti-IIa activity.
• It prevents clot formation and propagation rather than directly lysing clots.
• IV administration provides rapid anticoagulation.

Source: [Lecture] TWG Coag pp. 11–13 | [First Aid] 2025 pp. 419, 441

B5LG4.1. Explain warfarin's molecular target and why its anticoagulant effect is delayed.

Answer: Warfarin inhibits VKORC1, decreasing regeneration of reduced vitamin K needed for γ-carboxylation of factors II, VII, IX, X, and proteins C and S. Previously synthesized functional coagulation factors remain in circulation until cleared, causing delayed full anticoagulation.

Extra Information:

• Factor VII decreases relatively early.
• Prothrombin II has a long half-life and delays full antithrombotic effect.
• Warfarin requires INR-guided dose adjustment.

Source: [Lecture] TWG Coag pp. 17–20, 37 | [First Aid] 2025 pp. 419, 441

B5LG4.1. Compare direct thrombin inhibitors and direct factor Xa inhibitors by their precise enzymatic targets.

Answer: Dabigatran directly inhibits thrombin IIa, preventing fibrinogen conversion to fibrin and thrombin-mediated amplification. Apixaban, rivaroxaban, and edoxaban inhibit factor Xa, reducing conversion of prothrombin to thrombin.

Extra Information:

• Unlike heparin, these direct inhibitors do not require antithrombin.
• They generally have rapid onset compared with warfarin.
• Routine INR testing is not used for their dose adjustment.

Source: [Lecture] TWG Coag pp. 16, 22–24 | [First Aid] 2025 p. 441

B5LG4.1. Describe warfarin ADME, emphasizing plasma protein binding and CYP metabolism.

Answer: Warfarin is orally absorbed, highly albumin-bound, and hepatically metabolized. S-warfarin is metabolized mainly by CYP2C9, while other CYP enzymes contribute to R-warfarin metabolism. Metabolites are eliminated primarily through urine and bile.

Extra Information:

• High protein binding contributes to important drug interaction considerations.
• Hepatic metabolism contributes to variable dosing requirements.
• Drug and dietary interactions can significantly alter INR.

Source: [Lecture] TWG Coag pp. 17–20 | [First Aid] 2025 p. 441

B5LG4.1. Compare the major pharmacokinetic considerations of dabigatran and oral factor Xa inhibitors.

Answer: Dabigatran is administered as dabigatran etexilate and undergoes conversion to active dabigatran, which has substantial renal elimination. Apixaban, rivaroxaban, and edoxaban are orally active direct Xa inhibitors with differing renal elimination fractions and P-glycoprotein or CYP interactions.

Extra Information:

• Dabigatran elimination is approximately 80% renal.
• Apixaban has less renal elimination than dabigatran.
• Rivaroxaban therapeutic 15–20 mg dosing requires food for adequate absorption.

Source: [Lecture] TWG Coag pp. 16, 22–24

B5LG4.2. Compare UFH, LMWH, and fondaparinux by anti-IIa versus anti-Xa activity.

Answer: UFH has sufficient chain length to support antithrombin-mediated inhibition of both thrombin and Xa. LMWH contains shorter chains and has proportionally greater anti-Xa activity. Fondaparinux is a synthetic pentasaccharide that selectively accelerates antithrombin-mediated Xa inhibition.

Extra Information:

• UFH has approximately 1:1 anti-Xa to anti-IIa activity.
• LMWH commonly has approximately 2:1 to 4:1 anti-Xa predominance.
• Fondaparinux does not provide clinically significant thrombin inhibition.

Source: [Lecture] TWG Coag pp. 11–13

B5LG4.2. Compare UFH and LMWH routes, clearance, half-life, and monitoring.

Answer: UFH is administered IV or SC, has a short dose-dependent half-life, and undergoes substantial nonrenal clearance. Therapeutic IV UFH is monitored with aPTT or anti-Xa. LMWH is typically given SC, has more predictable bioavailability, longer duration, and predominantly renal elimination.

Extra Information:

• LMWH usually does not require routine laboratory monitoring.
• Anti-Xa monitoring may be used in selected patients.
• UFH is often useful in severe renal dysfunction or when rapid adjustment is necessary.

Source: [Lecture] TWG Coag pp. 12–15

B5LG4.2. Why is UFH often preferred in severe renal dysfunction or when urgent surgery may be necessary?

Answer: UFH has substantial nonrenal clearance, a short half-life, and effective reversal with protamine. LMWH depends more heavily on renal clearance and has a longer effect, creating accumulation risk and making immediate reversal less predictable.

Extra Information:

• Severe kidney dysfunction increases bleeding risk with renally cleared anticoagulants.
• UFH infusion can be titrated using coagulation monitoring.
• Protamine reverses LMWH only partially.

Source: [Lecture] TWG Coag pp. 12–15

B5LG4.2. Explain the immune mechanism of heparin-induced thrombocytopenia.

Answer: HIT is caused by IgG antibodies against platelet factor 4-heparin complexes. These antibodies activate platelet FcγRIIa receptors, promoting platelet activation, thrombin generation, and platelet consumption. The result is thrombocytopenia with paradoxically increased thrombotic risk.

Extra Information:

• HIT is more common with UFH than LMWH.
• Platelet reduction usually develops several days after exposure.
• Stop heparin and initiate a suitable nonheparin anticoagulant when HIT is strongly suspected.

Source: [Lecture] TWG Coag pp. 12–13, 31–34 | [First Aid] 2025 p. 419

B5LG4.2. Compare protamine effectiveness for UFH, LMWH, and fondaparinux.

Answer: Protamine is a positively charged compound that neutralizes negatively charged heparin. It effectively reverses UFH, only partially reverses LMWH, and does not meaningfully reverse fondaparinux.

Extra Information:

• Protamine should not be assumed to reverse all indirect factor Xa inhibitors.
• UFH's short half-life also facilitates management of bleeding.
• Severe hemorrhage requires anticoagulant cessation and supportive treatment.

Source: [Lecture] TWG Coag pp. 13, 33–34 | [First Aid] 2025 p. 442

B5LG4.3. Identify vitamin K-dependent coagulation proteins and explain the role of γ-carboxylation.

Answer: Factors II, VII, IX, and X and proteins C and S require vitamin K-dependent γ-carboxylation of glutamate residues. This creates calcium-binding sites that allow coagulation proteins to associate with negatively charged phospholipid membranes.

Extra Information:

• Warfarin decreases production of functional forms of these proteins.
• Factor V is not vitamin K-dependent.
• γ-carboxylation occurs during hepatic protein processing.

Source: [Lecture] TWG Coag pp. 5, 17, 37 | [First Aid] 2025 p. 419

B5LG4.3. Recall the relative half-lives of the vitamin K-dependent factors and identify which falls first after warfarin initiation.

Answer: Factor VII has the shortest procoagulant factor half-life, approximately 4–6 hours. Factor IX has a half-life of approximately 24 hours, factor X approximately 24–72 hours, and factor II approximately 60–72 hours. Protein C also has a short half-life, approximately 6–8 hours.

Extra Information:

• Factor VII depletion explains early PT/INR elevation.
• Prothrombin II depletion takes longer.
• Exact half-life estimates vary somewhat among sources.

Source: [Lecture] Applied Coagulation PFN pp. 26–27 | TWG Coag p. 37

B5LG4.3. Why can warfarin initiation produce a transient hypercoagulable state?

Answer: Warfarin rapidly reduces functional protein C, a natural anticoagulant, while longer-lived procoagulant factors such as prothrombin remain active. The temporary imbalance can favor clot formation despite an early increase in INR.

Extra Information:

• Warfarin-induced skin necrosis can result from microvascular thrombosis.
• Acute VTE treatment with warfarin requires appropriate initial parenteral anticoagulation.
• Protein C deficiency increases susceptibility to this complication.

Source: [Lecture] TWG Coag pp. 17, 31, 37–38 | [First Aid] 2025 p. 441

B5LG4.3. Explain why heparin overlap is required when warfarin is initiated for acute venous thromboembolism.

Answer: Heparin produces immediate anticoagulation through antithrombin, while warfarin requires several days to reduce existing vitamin K-dependent coagulation factors. Overlap prevents unprotected thrombosis during warfarin's delayed onset.

Extra Information:

• The lecture requires at least 5 days of overlap during warfarin initiation for acute VTE.
• INR must reach the required therapeutic range before stopping parenteral anticoagulation.
• Early INR elevation does not guarantee full suppression of factor II activity.

Source: [Lecture] TWG Coag pp. 17, 20, 38

B5LG4.3. Why can PT/INR rise before warfarin has achieved full antithrombotic effect?

Answer: Factor VII has a much shorter half-life than prothrombin, so its activity decreases rapidly and prolongs PT. Factor II remains in circulation longer, allowing substantial thrombin generation despite the elevated early INR.

Extra Information:

• This explains the distinction between early laboratory effect and full clinical anticoagulation.
• Factor VII is part of the extrinsic pathway.
• Heparin bridging is used for acute VTE when initiating warfarin.

Source: [Lecture] TWG Coag pp. 17, 20, 37 | [First Aid] 2025 p. 441

B5LG4.4. Identify baseline evaluations needed before warfarin initiation and explain their purpose.

Answer: Obtain baseline PT/INR, CBC, renal function, liver function, pregnancy status when relevant, and medication and dietary histories. These identify bleeding risks, altered coagulation synthesis, contraindications, and potential interactions affecting warfarin dose.

Extra Information:

• Warfarin is teratogenic.
• Liver dysfunction changes clotting-factor synthesis.
• CYP2C9 and VKORC1 variation can influence dose response.

Source: [Lecture] TWG Coag pp. 18–20

B5LG4.4. Identify common INR targets and monitoring considerations during warfarin therapy.

Answer: The lecture lists INR 2.0–3.0 for most AF and VTE indications and 2.5–3.5 for mechanical mitral valves. INR is checked frequently during initiation and after dose or interacting medication changes, then less frequently once stable.

Extra Information:

• Target INR depends on indication and valve characteristics.
• Diet and medication changes may alter INR.
• INR reflects standardized PT, not total hemostatic function.

Source: [Lecture] TWG Coag p. 20

B5LG4.4. Explain how to manage major bleeding during warfarin therapy.

Answer: Stop warfarin, stabilize the patient, identify and control bleeding, administer IV vitamin K, and rapidly replace coagulation factors with four-factor PCC when indicated. Vitamin K restores hepatic factor synthesis, while PCC supplies functional factors immediately.

Extra Information:

• PCC provides factors II, VII, IX, and X.
• Vitamin K does not immediately replace existing missing factors.
• Supportive treatment may include blood products and local hemostasis.

Source: [Lecture] TWG Coag pp. 20, 33–34 | [First Aid] 2025 p. 442

B5LG4.4. Why does dietary vitamin K variation affect warfarin anticoagulation?

Answer: Warfarin blocks vitamin K recycling rather than eliminating vitamin K itself. Increased dietary vitamin K can provide more substrate for hepatic γ-carboxylation and reduce anticoagulant effect, while decreased intake can increase warfarin sensitivity.

Extra Information:

• Consistency of vitamin K intake is generally more important than complete avoidance.
• Antibiotics and other medications can alter warfarin response.
• INR monitoring guides dose adjustment.

Source: [Lecture] TWG Coag pp. 18–20 | [First Aid] 2025 p. 441

B5LG4.4. Why is a high INR not equivalent to measuring all physiological clotting abnormalities?

Answer: INR standardizes PT, which primarily assesses the extrinsic and common coagulation pathways. It does not directly measure platelet function, all intrinsic factors, fibrinolysis, or the overall balance between procoagulant and anticoagulant systems.

Extra Information:

• INR is validated for warfarin monitoring.
• It does not accurately describe every bleeding disorder.
• Clinical context and additional testing remain essential.

Source: [Lecture] Applied Coagulation PFN pp. 12–17, 28–30 | TWG Coag p. 20

B5LG4.5. Compare warfarin with DOACs in onset, monitoring, and drug interactions.

Answer: Warfarin has delayed onset, substantial food and drug interactions, variable dose requirements, and requires INR monitoring. DOACs have relatively rapid onset, more predictable anticoagulant effects, and generally do not require routine coagulation testing.

Extra Information:

• Renal function affects selection and dosing of multiple DOACs.
• Adherence is important because DOAC effects decline relatively quickly after missed doses.
• Warfarin is preferred in selected conditions involving mechanical valves.

Source: [Lecture] TWG Coag pp. 24–30 | [First Aid] 2025 pp. 441–442

B5LG4.5. Compare dabigatran, apixaban, rivaroxaban, and edoxaban by enzymatic target.

Answer: Dabigatran inhibits thrombin IIa directly. Apixaban, rivaroxaban, and edoxaban inhibit factor Xa directly. Thrombin inhibition prevents fibrin formation and amplification, while Xa inhibition decreases thrombin generation upstream.

Extra Information:

• None requires antithrombin for inhibition.
• These agents prevent thrombus formation and propagation.
• Their elimination and interaction profiles differ.

Source: [Lecture] TWG Coag pp. 16, 22–24 | [First Aid] 2025 p. 441

B5LG4.5. Compare the renal elimination of dabigatran, apixaban, rivaroxaban, and edoxaban.

Answer: The lecture reports approximately 80% renal elimination for dabigatran, 27% for apixaban, 33% unchanged renal elimination for rivaroxaban, and 50% for edoxaban. These differences affect dosing and drug selection in renal impairment.

Extra Information:

• Dabigatran exposure is particularly sensitive to declining kidney function.
• Rivaroxaban and apixaban also have important P-glycoprotein and CYP interactions.
• Renal thresholds vary by indication and drug.

Source: [Lecture] TWG Coag pp. 16, 22–24

B5LG4.5. Which clinical conditions favor warfarin over DOAC therapy?

Answer: Mechanical heart valves, moderate-to-severe rheumatic mitral stenosis with AF, and high-risk triple-positive antiphospholipid syndrome are important situations favoring warfarin rather than routine DOAC therapy.

Extra Information:

• DOAC trials generally excluded mechanical-valve patients.
• Warfarin requires INR monitoring.
• Clinical indication must be assessed before selecting an anticoagulant.

Source: [Lecture] TWG Coag pp. 24–25, 28–30 | [Research] 2023 ACC/AHA/ACCP/HRS AF Guideline, Antithrombotic Therapy

B5LG4.5. Distinguish the major adverse effects and reversal approaches for different oral anticoagulants.

Answer: All oral anticoagulants increase bleeding risk. Warfarin can cause fetal toxicity and skin necrosis and is reversed with vitamin K plus PCC for severe bleeding. Dabigatran can cause dyspepsia and is reversed with idarucizumab. Major factor Xa inhibitor bleeding may require factor replacement strategies.

Extra Information:

• Drug elimination affects duration of anticoagulant activity.
• Renal impairment can increase DOAC exposure.
• The 2026 lecture reflects the withdrawal of Andexxa from the US market.

Source: [Lecture] TWG Coag pp. 30–35 | [First Aid] 2025 pp. 441–442 | [Research] FDA Andexxa Safety Communication, Dec. 22, 2025

B5LG4.6. Develop an initial anticoagulation plan for hemodynamically stable acute PE.

Answer: Begin therapeutic anticoagulation when indicated after evaluating bleeding risk and contraindications. Appropriate options include selected DOAC regimens or parenteral anticoagulation followed by an oral agent, accounting for renal function, clotting disorders, and clinical circumstances.

Extra Information:

• Apixaban and rivaroxaban have initial PE treatment regimens that do not require heparin lead-in.
• Dabigatran and edoxaban require initial parenteral anticoagulation for acute VTE.
• Anticoagulants prevent clot extension and additional emboli.

Source: [Lecture] TWG Coag pp. 7–9, 23–25 | [First Aid] 2025 p. 691

B5LG4.6. Explain why thrombolysis is considered for high-risk PE with shock but not routinely for stable PE.

Answer: A large PE can markedly increase pulmonary vascular resistance, producing RV failure and obstructive shock. Thrombolytics activate plasmin formation and accelerate fibrin breakdown, potentially restoring pulmonary blood flow. Their major bleeding risk generally limits routine use in stable PE.

Extra Information:

• Hemodynamic instability is an important treatment distinction.
• Intracranial hemorrhage is a major thrombolytic complication.
• Reperfusion decisions require contraindication assessment.

Source: [Lecture] TWG Coag pp. 8–9, 21 | [First Aid] 2025 pp. 442, 691

B5LG4.6. How does renal dysfunction influence selection of an anticoagulant for acute PE?

Answer: Severe renal dysfunction increases accumulation risk with anticoagulants that depend heavily on renal elimination. UFH is often useful because it has a short half-life, substantial nonrenal clearance, adjustable infusion dosing, and effective protamine reversal.

Extra Information:

• LMWH and dabigatran have substantial renal elimination.
• DOAC dose adjustments depend on agent and indication.
• Renal function should be assessed before starting treatment.

Source: [Lecture] TWG Coag pp. 12–16, 22–24

B5LG4.6. Explain why anticoagulants prevent thrombus propagation but do not directly dissolve an established clot.

Answer: Anticoagulants inhibit enzymes or cofactors needed to generate new fibrin, reducing clot growth and additional thrombosis. Existing thrombus removal depends on endogenous fibrinolysis or externally administered thrombolytic therapy.

Extra Information:

• Heparin accelerates antithrombin inhibition.
• DOACs directly inhibit thrombin or Xa.
• Alteplase promotes plasmin-mediated fibrin degradation.

Source: [Lecture] TWG Coag pp. 6, 21 | [First Aid] 2025 pp. 441–442

B5LG4.6. What factors determine whether extended anticoagulation is appropriate after PE?

Answer: Evaluate whether the event was provoked or unprovoked, recurrence risk, bleeding risk, history of prior VTE, renal and liver function, contraindications, drug interactions, and patient preference. Continue treatment when expected thrombosis-prevention benefit outweighs bleeding risk.

Extra Information:

• Major transient provoking factors can influence planned duration.
• Recurrent or persistent-risk VTE may justify extended therapy.
• Patients require reassessment as clinical circumstances change.

Source: [Lecture] TWG Coag pp. 23–30

B5LG4.7. Match UFH, LMWH, and fondaparinux with the effectiveness of protamine reversal.

Answer: Protamine effectively neutralizes UFH, partially reverses LMWH, and does not meaningfully reverse fondaparinux. This reflects differing molecular structures and the ability of protamine to bind and neutralize their anticoagulant activity.

Extra Information:

• UFH has an additional advantage of a short half-life.
• Severe bleeding requires anticoagulant cessation.
• Supportive treatment is needed even when a specific reversal agent is available.

Source: [Lecture] TWG Coag pp. 13, 33–34 | [First Aid] 2025 p. 442

B5LG4.7. Match warfarin, dabigatran, and factor Xa inhibitors with clinically relevant reversal approaches.

Answer: Major warfarin bleeding is treated with IV vitamin K and four-factor PCC. Dabigatran is specifically reversed with idarucizumab, an antibody fragment that binds dabigatran. Four-factor PCC is an off-label strategy used for selected major factor Xa inhibitor-associated bleeding.

Extra Information:

• Dialysis can remove dabigatran in selected situations.
• The FDA reports Andexxa US sales ended December 22, 2025.
• Treatment includes supportive care and control of the bleeding source.

Source: [Lecture] TWG Coag pp. 32–35 | [Research] FDA Andexxa Safety Communication, Dec. 22, 2025

B5LG4.7. Explain the mechanisms of desmopressin and recombinant factor VIIa in selected bleeding disorders.

Answer: Desmopressin promotes endothelial release of VWF and factor VIII, improving platelet adhesion and selected factor deficiencies. Recombinant factor VIIa promotes factor X activation and thrombin generation, helping bypass selected coagulation abnormalities.

Extra Information:

• Desmopressin may be used in selected VWD, mild hemophilia A, and uremic platelet dysfunction.
• Recombinant factor VIIa may be used for selected hemophilia patients with inhibitors.
• Neither drug is routine DOAC reversal therapy.

Source: [Lecture] TWG Coag pp. 32–34 | [First Aid] 2025 pp. 418–419

B5LG4.7. Compare the roles of fresh frozen plasma, four-factor PCC, and tranexamic acid.

Answer: FFP supplies multiple soluble clotting factors. Four-factor PCC provides concentrated vitamin K-dependent factors II, VII, IX, and X. Tranexamic acid inhibits plasminogen activation and reduces fibrin breakdown, stabilizing existing clots.

Extra Information:

• PCC provides factor replacement more rapidly and with less volume than FFP in appropriate situations.
• FFP is useful when broader factor replacement is required.
• Antifibrinolytics do not replace missing coagulation factors.

Source: [Lecture] TWG Coag pp. 33–34 | [First Aid] 2025 pp. 418, 442

B5LG4.7. Why must anticoagulant reversal decisions account for the severity and site of bleeding?

Answer: Reversal exposes the patient to renewed thrombotic risk while helping restore hemostasis. Major or life-threatening hemorrhage generally warrants urgent reversal when appropriate, whereas minor bleeding may be managed with medication interruption and supportive care.

Extra Information:

• Intracranial hemorrhage is particularly high risk.
• Renal function affects drug clearance.
• The treatment decision requires balancing bleeding severity and thrombosis risk.

Source: [Lecture] TWG Coag pp. 30–35

B5S1. Compare unstable angina, NSTEMI, and STEMI by myocardial ischemia and necrosis.

Answer: Unstable angina involves acute myocardial ischemia without detectable necrosis. NSTEMI involves myocardial injury with elevated troponin and commonly subendocardial infarction. STEMI usually reflects acute severe coronary obstruction with extensive ischemic injury and commonly transmural infarction.

Extra Information:

• All three can result from acute coronary plaque disruption.
• Prolonged ischemia produces irreversible cardiomyocyte injury.
• Clinical ECG patterns are not perfectly equivalent to infarct depth.

Source: [Lecture] Structure HF Prework pp. 3–5 | B5 Heart Failure Pathology p. 4 | [First Aid] 2025 p. 308

B5S1. Compare ECG and cardiac troponin patterns in unstable angina, NSTEMI, and STEMI.

Answer: Unstable angina may show ST depression or T-wave inversion without troponin elevation. NSTEMI produces troponin elevation, commonly with ST depression or T-wave inversion. STEMI typically produces ST elevation in anatomically related leads with elevated troponin.

Extra Information:

• Serial ECGs and troponins may be necessary.
• Troponin establishes myocardial injury but is not specific to plaque rupture.
• Coronary territory helps interpret ST-elevation distribution.

Source: [Lecture] Structure HF Prework p. 5 | [First Aid] 2025 pp. 308–310

B5S1. Explain why reduced coronary oxygen supply or increased myocardial oxygen demand can produce ischemia.

Answer: Ischemia occurs when myocardial oxygen consumption exceeds coronary oxygen delivery. Acute thrombosis decreases supply, while tachycardia, increased contractility, elevated afterload, and increased ventricular wall stress increase demand.

Extra Information:

• Heart rate influences both demand and diastolic coronary perfusion time.
• Coronary blood flow and arterial oxygen content determine oxygen supply.
• Severe anemia or systemic illness can produce supply-demand mismatch.

Source: [Lecture] Structure HF Prework pp. 3–5 | [First Aid] 2025 pp. 289, 308

B5S2. Describe the earliest myocardial changes after transmural infarction, including wavy fibers and coagulative necrosis.

Answer: Severe ischemia depletes ATP, disrupts ion homeostasis, and eventually causes irreversible cardiomyocyte injury. Wavy myocardial fibers may appear in the first 1–3 hours. Coagulative necrosis, contraction bands, edema, hemorrhage, and early neutrophilic infiltration become apparent during subsequent hours.

Extra Information:

• The lecture places important early histologic changes around 4–12 hours.
• Coagulative necrosis temporarily preserves tissue architecture.
• Reperfusion can produce prominent contraction-band injury.

Source: [Lecture] B5 Heart Failure Pathology p. 3 | [First Aid] 2025 p. 309

B5S2. Describe the histologic findings approximately 1–3 days after MI.

Answer: Myocardial coagulative necrosis becomes prominent, with loss of nuclei and cross-striations and heavy neutrophilic infiltration. These inflammatory cells begin removing necrotic tissue and contribute to the evolving appearance of acute myocardial infarction.

Extra Information:

• Neutrophils dominate the early inflammatory phase.
• Gross findings can include mottling and yellowing.
• Electrical instability and ventricular dysfunction can occur during this period.

Source: [Lecture] B5 Heart Failure Pathology p. 3 | [First Aid] 2025 p. 309